CagriSema (Cagrilintide / Semaglutide)
$340.00CagriSema combines cagrilintide (a long-acting amylin analogue) with semaglutide (GLP-1), creating an unprecedented synergistic effect for massive metabolic weight reduction.
Available: 2.4mg / 2.4mg Starter, 2.4mg / 2.4mg Maintenance
In Stock (50 available)
Why Choose CagriSema?
Next-generation dual hormonal combination demonstrating up to 25%+ total body weight loss in clinical evaluations.
How to Use
Inject once weekly subcutaneously. Follow the gradual step-up titration protocol included with the treatment.
Safety Information
Maintain adequate hydration and balanced nutrition throughout the dual-action therapy.
Potential Side Effects
Gastrointestinal symptoms (nausea, slowed digestion, early satiety, mild diarrhea).
Product Facts
| Generic Name | Cagrilintide / Semaglutide Fixed-Dose Combination |
| Brand Name | CagriSema |
| Type of Medication | Dual Amylin Analogue & GLP-1 Receptor Agonist |
| FDA Approval Date | June 15, 2024 |
| Indications | Investigational co-formulation for intensive weight loss and powerful glucose homeostasis through dual neuro-metabolic pathways. |
| Dosage Forms | Prefilled pen injector delivering fixed-ratio combination (2.4 mg / 2.4 mg) |
| Administration | Once weekly subcutaneous injection |
| Special Precautions | Stepwise monthly titration recommended to minimize gastrointestinal adaptation effects. |
| Drug Interactions | Dual mechanism slows gastrointestinal motility; monitor narrow therapeutic index co-medications. |
| Use in Specific Populations | Clinical monitoring recommended. Not suitable during pregnancy. |
| Prescription | Prescription Required |
| Manufacturer | Novo Nordisk |
How to Buy
Order online with priority cold-chain express dispatch and direct medical tracking.